Nucana Plc (NCNA)
$3.79
Insights on Nucana Plc
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 46.7% return, outperforming this stock by 129.1%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 245.1% return, outperforming this stock by 341.4%
Performance
- $3.61$4.20$3.79
4.75%
Downside
Day's Volatility :14.13%
Upside
9.85%
- $3.79$23.75$3.79
0.0%
Downside
52 Weeks Volatility :84.04%
Upside
84.04%
Returns
| Period | Nucana Plc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -47.07% | -0.7% | 0.0% |
6 Months | -74.26% | 6.6% | 0.0% |
1 Year | -82.36% | 3.7% | -1.5% |
3 Years | -96.19% | 14.0% | -21.8% |
Highlights
Market Capitalization | 209.9M |
Book Value | $7.11 |
Earnings Per Share (EPS) | -16.51 |
Wall Street Target Price | 124.96 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -45.16% |
Return On Equity TTM | -103.51% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -30.7M |
Diluted Eps TTM | -16.51 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -12.67 |
EPS Estimate Next Year | -12.51 |
EPS Estimate Current Quarter | -0.13 |
EPS Estimate Next Quarter | -0.11 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 3197.1%
Technicals Summary
Sell
Neutral
Buy
Nucana Plc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Nucana Plc | -56.73% | -74.26% | -82.36% | -96.19% | -98.83% |
 Moderna, Inc. | -0.79% | 20.27% | -27.48% | -36.11% | 359.53% |
 Regeneron Pharmaceuticals, Inc. | -6.12% | 9.1% | 11.53% | 80.35% | 170.35% |
 Novo Nordisk A/s | -6.29% | 23.82% | 46.7% | 242.59% | 414.69% |
 Vertex Pharmaceuticals Incorporated | -4.44% | 6.95% | 20.9% | 79.35% | 133.77% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Nucana Plc | NA | NA | NA | -12.67 | -1.04 | -0.45 | NA | 7.11 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 25.71 | 25.71 | 1.46 | 45.13 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 46.58 | 46.58 | 2.4 | 3.33 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.42 | 28.42 | 0.53 | 16.73 | 0.23 | 0.13 | NA | 68.22 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Nucana Plc | Buy | $209.9M | -98.83% | NA | 0.0% |
Moderna, Inc. | Buy | $39.8B | 359.53% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $98.1B | 170.35% | 25.71 | 30.14% |
Novo Nordisk A/s | Buy | $551.2B | 414.69% | 46.58 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $101.9B | 133.77% | 28.42 | 36.68% |
Institutional Holdings
Sofinnova Ventures
0.35%Baillie Gifford & Co Limited.
0.28%The Carlyle Group Inc
0.25%Acadian Asset Management LLC
0.04%Renaissance Technologies Corp
0.04%
Corporate Announcements
Nucana Plc Earnings
Nucana Plc’s price-to-earnings ratio stands at None
Read More
Company Information
nucana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer by applying our phosphoramidate chemistry technology to transform some of the most widely prescribed chemotherapy agents into more effective and safer medicines. while these conventional agents remain part of the standard of care for the treatment of many solid tumours, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated. utilising our proprietary protide technology, we are developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells.
Organization | Nucana Plc |
Employees | 25 |
CEO | Mr. Hugh Stephen Griffith |
Industry | Health Technology |
